20% off purchase of 3 or more products* | Learn More >>

Monoclonal Antibody Chromatin Ip-Seq Histone Demethylase Activity

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Chromatin IP, Chromatin IP-seq, Immunoprecipitation, Western Blotting

Background: PHD finger protein 8 (PHF8) is a histone lysine demethylase that functions as a transcriptional activator by specifically demethylating a number of repressive histone methylation marks: mono- and di-methyl-histone H3 Lys9 (H3K9me1 and H3K9me2), di-methyl-histone H3 Lys27 (H3K27me2) and mono-methyl-histone H4 Lys20 (H4K20me1). PHF8 contains an N-terminal zinc finger-like PHD domain that binds tri-methylated histone H3 Lys4 (H3K4Me3) and a C-terminal jumonji domain that is responsible for the demethylase activity (1). Deletion and point mutations (F279S) in the jumonji domain of PHF8 are associated with the onset of X-linked mental retardation (XLMR). In addition, PHF8 is highly expressed in prostate cancer, laryngeal squamous cell carcinoma, and human non-small-cell lung cancer (NSCLC). Its expression is predictive of poor survival (2-4). Overexpression of PHF8 increases cell proliferation and cell motility, while silencing of PHF8 reduces cell proliferation, migration, and invasion (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse

Application Methods: Chromatin IP, Chromatin IP-seq, Immunoprecipitation, Western Blotting

Background: The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX) and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is over-expressed in many breast cancers and may act by repressing multiple tumor suppressor genes including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is largely uncharacterized.

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Chromatin IP, Chromatin IP-seq, Immunoprecipitation, Western Blotting

Background: Jumonji/ARID domain-containing protein 2 (JARID2) is a founding member of the JmjC-domain-containing protein family that is involved in regulation of histone methyltransferase activity (1,2). While many proteins in this family are protein demethylases, JARID2 lacks several conserved residues in the catalytic domain and does not exhibit protein demethylase activity (1,2). Research studies indicate that JARID2 is a nuclear protein that is highly expressed in poorly differentiated and actively dividing cells, with expression decreasing upon cellular differentiation (3,4). Expression of JARID2 protein is essential for embryonic development as the protein plays an important role in regulation of heart and liver development, neural tube fusion, and hematopoiesis (4). JARID2 is an accessory component of the polycomb repressor complex 2 (PRC2), which represses target gene expression through methylation of histone H3 at lysine 27 by EZH2 methyltransferase (5-10). JARID2 recruits the PRC2 complex to target genes and increases EZH2 methyltransferase activity by binding to nucleosomes and DNA (5-10). Additional studies show that loss of JARID2 expression results in decreased recruitment of PRC2, decreased methylation of histone H3 at lysine 27 at target genes, and delayed and incomplete differentiation of embryonic stem cells (5-10). Experimental knockdown of JARID2 in Xenopus laevis impairs the induction of gastrulation genes in blastula embryos and results in differentiation failure (5).